Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock Rated “Moderate Buy” by Wall Street BrokeragesDefense World · 4 days ago
Head-To-Head Survey: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) versus Mirum Pharmaceuticals (NASDAQ:MIRM)Defense World · Oct 16, 2026
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire · Oct 15, 2026
Mirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver DiseasesZacks Investment Research · Oct 13, 2026
Mirum Pharmaceuticals, Inc. (MIRM) Discusses Phase 3 EXPAND Study Results for Maralixibat in Cholestatic Pruritus Including Biliary Atresia TranscriptSeeking Alpha · Oct 12, 2026
Mirum Pharmaceuticals’ LIVMARLI Study Hits Key Endpoints in Rare Liver DiseasesDefense World · Oct 12, 2026Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 5, 2026 | -$0.74 | -$1.06 | Miss |
| May 6, 2026 | -$0.40 | -$13.43 | Miss |
| Feb 25, 2026 | $0.02 | -$0.11 | Miss |
| Nov 4, 2025 | -$0.10 | $0.05 | Beat |
| Aug 6, 2025 | -$0.31 | -$0.12 | Beat |
| May 7, 2025 | -$0.39 | -$0.30 | Beat |